A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects

Authors and affiliations

Hannah Hartland¹*, Kimia Mahdavi¹*, Luke A Jelen^{1,2}, Rebecca Strawbridge¹, Allan H Young^{1,2}, Laith Alexander^{1,2+}

 ¹ Department of Psychological Medicine, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
 ² South London and Maudsley NHS Foundation Trust, London, United Kingdom.
 *Joint first authors
 *Corresponding author, laith.alexander@kcl.ac.uk

Keywords

ketamine, anxiety, anxiolytic, antidepressant, dissociation, meta-analysis

Abstract

Background: Subanaesthetic doses of ketamine may be effective in treating symptoms of anxiety, but the time profile of ketamine's anxiolytic effect is ill-defined. This systematic review and meta-analysis of randomised controlled trials investigated the anxiolytic effect of ketamine at different time points across a range of clinical contexts. Methods: Electronic databases were searched to capture randomised control trials measuring the anxiolytic effects of ketamine across a range of clinical settings including mood disorders, anxiety disorders and chronic pain. Meta-analyses were conducted using a random-effects model. The correlations between (1) improvements in mean anxiety and depression scores, and (2) peak dissociation and improvements in mean anxiety scores were also assessed.

Results: 14 studies met inclusion criteria. Risk of bias was high in 11 studies. Ketamine significantly reduced anxiety scores compared to placebo at the acute (<12 hours; SMD: -

1.07 [95% CI: -1.68, -0.46], p < 0.001), subacute (24 hours; SMD: -0.43 [95% CI: -0.65, -0.22], p < 0.001) and sustained (7-14 days; SMD: -0.43 [95% CI: -0.65, -0.20], p < 0.001) time points. Exploratory analyses revealed improvements in anxiety and depression symptoms correlated at both subacute ($R^2 = 0.621$, p = 0.035) and sustained time points ($R^2 = 0.773$, p = 0.021). The relationship between peak dissociation and improvement in anxiety was not significant.

Conclusions: Ketamine appears to offer rapid and sustained relief from anxiety symptoms across a range of clinical settings, with anxiolytic effects occurring within the first 12 hours of administration and remaining effective for one to two weeks. Future studies with improved blinding could explore ketamine maintenance therapy for anxiety.

Introduction

Anxiety disorders are common, with a lifetime prevalence of 33.7% in United States adults (Bandelow & Michaelis, 2015). These disorders share a common factor of fear and anxiety which impair daily functioning but differ in the situations or objects catalysing the schema (American Psychiatric Association, 2013). Significant anxiety symptoms are seen in a range of clinical settings, including major depressive disorder (MDD) (Drysdale et al., 2017; Park & Kim, 2020), chronic pain (McWilliams et al., 2003), advanced cancer (Roth & Massie, 2007), and palliative care (Kelly et al., 2006; Kozlov et al., 2019; Neel et al., 2015).

Current treatments for pathological anxiety include selective serotonin reuptake inhibitors (SSRIs), but these have a slow onset of action and can paradoxically worsen anxiety upon initiation (Cassano et al., 2002; Nutt, 2005). Benzodiazepines provide rapid relief of acute anxiety symptoms, but are associated with tolerance and dependence (Bystritsky, 2006; Cassano et al., 2002). Given these issues and the prevalence of treatment-resistant anxiety (Bystritsky, 2006), there is a pressing need for the development of novel rapidly acting anxiolytic agents with the potential for intermediate to long-term administration.

One avenue which may meet this need comes in the form of the N-methyl-D-aspartic acid (NMDA) receptor antagonist, ketamine. Ketamine is an effective glutamate-based antidepressant (Marcantoni et al., 2020), but evidence has also emerged supporting its anxiolytic effects. In patients with social anxiety disorder (SAD) (Glue et al., 2018; Taylor et al., 2018), obsessive-compulsive disorder (OCD) (Bandeira et al., 2022), post-traumatic stress disorder (PTSD) (Liriano et al., 2019), and treatment-refractory anxiety (Tully et al., 2022), ketamine may have fast-acting anxiolytic effects lasting approximately one to two weeks after a single dose.

Several review articles have inferred ketamine's utility in the treatment of anxiety disorders and have supported this suggestion (Banov et al., 2020; Tully et al., 2022; Whittaker et al., 2021). However, these reviews did not examine the time course of ketamine's action, and included open-label studies, uncontrolled trials, case series, and other lower quality studies, limiting the conclusions that can be drawn about ketamine's anxiolytic effects compared to

placebo. Furthermore, the transdiagnostic nature of anxiety symptoms, as emphasised by the negative valence system in the *Research Domain Criteria* (Insel et al., 2010) and the fear and distress subfactors in the *Hierarchical Taxonomy of Psychopathology* (Kotov et al., 2017), means that ketamine may prove to be useful in a range of clinical settings associated with distressing anxiety symptoms and this has yet to be explored.

The purpose of this systematic review and meta-analysis is to examine the effect of ketamine on symptoms of anxiety at several time points, through synthesizing the findings of blinded, randomised, placebo-controlled trials (RCTs). Our principal analyses explored ketamine's anxiolytic effects acutely (< 12 hours), subacutely (at 24 hours) and at a sustained time point (7-14 days), incorporating data from RCTs measuring anxiety symptoms in anxiety disorders, depression & other mood disorders, chronic pain, and palliative care settings.

Methods

This review was carried out in accordance with PRISMA guidance. We registered the protocol for this review with the PROSPERO International prospective register of systematic reviews (CRD42022303070; <u>URL</u>). In addition to the protocol described on PROSPERO, we collected depression and dissociation data and correlated these against changes in anxiety scores as described in **Data extraction and analysis**.

Inclusion and exclusion criteria

Our inclusion criteria were:

- **Study type**: single or double blinded RCT written in English (including crossover trials)
- Population: adult human patients suffering from anxiety disorders of any type (including post-traumatic stress disorder [PTSD] and obsessive-compulsive disorder [OCD]) or in whom anxiety symptoms were measured in the context of mood disorders, chronic pain or palliative care
- Intervention: subanaesthetic doses of either racemic ketamine, S-ketamine or Rketamine, administered via intravenous, intranasal, oral, subcutaneous, intramuscular or sublingual routes
- **Control**: an active or inactive placebo comparator
- **Outcome**: a primary or secondary outcome relating to anxiety

We excluded:

- Animal studies
- Non-RCT studies or where no party was blinded to treatment allocation
- Any studies where ketamine was used at anaesthetic doses or in the context of surgery/anaesthesia
- Any studies where ketamine was administered in the context of a medical or surgical emergency
- Studies with child or adolescent subjects

Search strategy

EMBASE (Ovid), MEDLINE (Ovid) and APA PsycINFO (Ovid) were systematically searched (February 2022) using keywords and medical subject headings relating to ketamine and anxiety: ketamine AND [(Anxiety OR Test Anxiety OR Anxiety Disorders OR Test Anxiety Scale) OR Obsessive-Compulsive Disorder OR Social Phobia OR Phobic Disorders OR Agoraphobia OR Post-Traumatic Stress Disorders OR Separation Anxiety OR (Panic Disorder OR Panic) OR Mutism OR (GAD-7 OR Patient Health Questionnaire) OR (Palliative Care OR "Hospice and Palliative Care Nursing" OR Palliative Medicine)] AND (Randomized Controlled Trial OR Clinical Trial) NOT Child. Additionally, the first 200 findings based on relevance of a Google Scholar search (February 2022) using keywords (ketamine AND anxiety) were examined.

Article screening and assessment for eligibility

Any duplicate titles and abstracts generated from the search were removed using Syras systematic review screening software (Scipilot Pty. Ltd., Sydney, Australia). The remaining articles were screened for potential relevance and eligibility according to pre-specified inclusion and exclusion criteria by three independent researchers, with others' ratings masked from their own.

Risk of Bias

To determine reliability and transparency of the studies, a risk of bias assessment was completed for each included RCT using the Cochrane risk-of-bias assessment tool for randomized trials (Higgins et al., 2011). The Cochrane tool explores bias over five domains: selection bias, performance bias, detection bias, attrition bias, and reporting bias. There is an additional domain for crossover trials which explores any carryover bias. Each study was judged across all domains as well as given an overall rating. The risk of bias assessment was completed independently by three reviewers, ensuring each study was double rated by two different reviewers. Disagreements were discussed and resolved through consensus.

Data extraction and analysis

Descriptive data were extracted by three independent reviewers and organised into a table (**Table 1**) including the type of study (single or double-blinded RCT), population (disorder, number and whether medication-free) studied, intervention used (type and dose(s) of ketamine, route of administration, and frequency of dosing if applicable), control used (details of the inactive or active placebo), and outcome measured (anxiety scale used; anxiety scores at time points measured).

Numerical data were extracted either directly from published papers (when available), from direct communication with authors, or from estimating graph values if needed. Extracted numerical data were then compiled using Review Manager (RevMan version 5.4), and RevMan was used to generate forest plots of the standard mean differences (SMDs) in anxiety scores between groups receiving ketamine *vs.* placebo. Separate analyses were carried out on three time points: less than 12 hours post-administration (acute); 24 hours post-administration (subacute); and 7-14 days post-administration (sustained). A time point beyond 14 days was also qualitatively assessed. To maximise comparability, when a study had multiple time points which fell under one of our pre-specified ranges, the modal time point that was available across studies was included (unless a study only had data available at a different time point). In the case of multiple anxiety outcomes, the primary outcome as defined by the study was used. In crossover trials where a carryover effect was identified by the authors, data from the first arm only were included in the meta-analysis.

Data were pooled across studies to conduct exploratory analyses of the correlation between improvements in anxiety scores post-ketamine and (1) improvements in depression scores post-ketamine and (2) peak Clinician-Administered Dissociative States Scale (CADSS) scores using linear regressions in R (version 3.5.3).

Results

Results for the systematic review and meta-analysis article search are summarised in the PRISMA flowchart (**Figure 1**). The combined searches generated 4647 records, leaving 4515 once duplicates were removed. After initial screening, 309 articles were included in the full-text review. Of these, 295 were deemed ineligible, and 14 RCTs were included in the qualitative systematic review. Due to missing and inaccessible data, 3 were excluded from quantitative analysis, meaning 11 articles were included in the meta-analysis.




Figure 1. PRISMA flow-chart.

Study characteristics and risk of bias

Information about each study, including design, sample sizes, ketamine dosing, control dosing, and outcome measures is reported in **Table 1**. Results of the Cochrane risk of bias analysis revealed that all but two studies had an overall rating of some concerns or high risk of bias (**Figure 2**). The most common domains of concern were deviations from intended interventions, selective reporting of results and carryover effects in two of the seven studies with crossover designs.

	Randomisation process	Period and carryover effects	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
Abdallah 2022							
Dadabayev 2020							
Fallon 2018							
Feder 2014							
Feder 2021							
Lapidus 2014							
Murrough 2015							
Norbury 2021							
Nugent 2018							
Pradhan 2017							
Pradhan 2018							
Rodriguez 2013							
Taylor 2018							
Zarate 2012							




Figure 2. Cochrane risk of bias table for included studies (*k* = 14).

The subsequent sections present analyses divided into ketamine's acute response (less than 12 hours; k = 6), subacute response (24 hours; k = 10), sustained response (7-14 days; k = 9), and responses beyond 14 days (k = 4). For a detailed summary of significant and non-significant findings of each study, see **Supplementary table 1**.

Acute (<12 hours)

Seven studies measured anxiety at one or more time points <12 hours after ketamine administration. Two of these studies did not report their findings (Lapidus et al., 2014; Pradhan et al., 2018). Of the rest, three reported that ketamine reduced anxiety significantly compared to placebo at at least one time point <12 hours (Nugent et al., 2018; Rodriguez et al., 2013; Zarate et al., 2012), and two reported non-significance compared to placebo (Pradhan et al., 2017; Taylor et al., 2018).

All three significant studies used intravenous ketamine. Zarate et al. (2012) (n = 15) and Nugent et al. (2018) (n = 35) explored anxiolytic effects in mood disorder participants, and Rodriguez et al. (2013) (n = 15) explored effects in patients with OCD. Zarate et al. (2012) found significant improvements in the Visual Analogue Scale for anxiety (VAS-Anxiety; Aitken, 1969) starting at 40 minutes post-infusion, which remained significant at 80 minutes, 110 minutes and 230 minutes. Nugent et al. (2018) found significant improvements in Hamilton Anxiety Scale (HAM-A; Hamilton, 1959) scores at 230 minutes, but not 40 minutes. Similarly, Rodriguez et al. (2013) found significant improvements in the Visual Analogue Scale for OCD (OCD-VAS; Rodriguez et al., 2011) scores at 230 minutes, but not 90 minutes and 110 minutes.

For the meta-analysis, group-level data were obtained for all five studies with reported data taken between three- and four-hours post-administration (**Figure 3A**). This meta-analysis included 69 patients who received ketamine and 63 who received placebo. Standardised mean differences (SMDs) were calculated for each study, as well as an overall SMD for the meta-analysis, which was significant in favour of ketamine compared to placebo (SMD: - 1.07, 95% CI: [-1.68, -0.46], *p* < 0.01). There was moderate heterogeneity among the studies, but this was not statistically significant ($I^2 = 51\%$, *p* = 0.08).

medRxiv preprint doi: https://doi.org/10.1101/2022.12.09.22283264; this version posted December 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Α.	Ke	etamine		PI	acebo		St	td. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Rodriguez 2013	2.2	1.697	8	6.1	0.926	7	11.9%	-2.63 [-4.12, -1.14]	
Zarate 2012	11.93	5.89		19.17	4.76	12	22.8%	-1.30 [-2.16, -0.44]	_
Faylor 2018	64.8	20.1	9	85.1	22.2	9	20.0%	-0.91 [-1.90, 0.07]	
Pradhan 2017		20.34	5		13.31	4		-0.88 [-2.30, 0.55]	
							12.8%		
Nugent 2019	14.36	6.67	33	17.35	4.44	31	32.5%	-0.52 [-1.02, -0.02]	
Total (95% CI)			69			63	100.0%	-1.07 [-1.68, -0.46]	◆
Heterogeneity: Tau ² :	= 0.23; 0	Chi ² = 8.	21, df	= 4 (P =	0.08);	$^{2} = 519$	%	-	
Test for overall effect									
		,	,						Favours ketamine Favours placebo
3.									
	к	etamine		1	Placebo		:	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Zarate 2012	13.36	6.91	14	20	4.55	12	6.4%	-1.08 [-1.92, -0.25]	(
Taylor 2018	66.11	19.572	9	86.25	21.75	9	4.6%	-0.93 [-1.91, 0.06]	
Murrough 2015	6.1	2.9	12	8.4	3.2	12	6.5%	-0.73 [-1.56, 0.10]	
Nugent 2019	15.45	7.06	33	18.37	4.78	30	17.8%	-0.47 [-0.98, 0.03]	
Feder 2014	14.7	23.452	19	24	17.436	22	11.6%	-0.45 [-1.07, 0.18]	
Feder 2021	19.7	15.2			13.1		8.6%	-0.35 [-1.07, 0.37]	
Abdallah 2022	31.01	20.7	51	37.93	20.8	54	30.1%	-0.33 [-0.72, 0.05]	
Pradhan 2017	25.6	3.78	5	26.6	7.63	4	2.6%	-0.15 [-1.47, 1.16]	
Pradhan 2018	25.8	8.15			6.82	10		-0.06 [-0.94, 0.81]	
Dabadayev 2020	36.3	17.28	11	37	15.78	10	6.1%	-0.04 [-0.90, 0.82]	
Total (95% CI)			179			178	100.0%	-0.43 [-0.65, -0.22]	•
Heterogeneity: Tau ²	= 0.00: 0	$2hi^{2} = 5.$	77. df =	= 9 (P =	0.76); I ²	² = 0%		-	
Test for overall effect									-4 -2 0 2 4 Favours ketamine Favours placebo
2.									
	Ke	etamine		F	lacebo			Std. Mean Difference	Std. Mean Difference
udy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
aylor 2018	67	20.7	9	87.75	23.16	9	5.4%	-0.90 [-1.88, 0.08]	
eder 2021	22.5	14.4	15	33.2	11.8	15	9.3%	-0.79 [-1.54, -0.04]	
odriguez 2013	18.25	7.305	8	23.714	6.343	7	4.6%	-0.75 [-1.81, 0.31]	
lurrough 2015	6	2.6	12	8.2	3.9	12	7.7%	-0.64 [-1.47, 0.18]	+
eder 2014	25.76	19.4	19	36.32	13.73	15	10.8%	-0.60 [-1.29, 0.09]	
arate 2012	16.67	5.25	12	18.91	3.02	11	7.5%	-0.50 [-1.33, 0.34]	+
ugent 2019	17.55	6.68	20	20	4.85	17	12.2%	-0.41 [-1.06, 0.25]	-++
abadayev 2020	28.2	22.6	11	33.67	20.4	10	7.0%	-0.24 [-1.10, 0.62]	-+
bdallah 2022		21.02	51		20.95				
otal (95% CI)			157			150	100.0%	-0.43 [-0.65, -0.20]	•
leterogeneity: Tau ² =	= 0.00 [.] C	$chi^2 = 4$	93. df	= 8 (P =	= 0.77).				
est for overall effect					···· /,				-4 -2 Ó Ż Favours ketamine Favours placebo

Figure 3. Forest plots. Left favours ketamine (indicates ketamine reduced anxiety scores compared to control). Error bars represent 95% confidence intervals. (**A**) Acute time point (<12 hours). (**B**) Subacute time point (24 hours). (**C**) Sustained time point (7-14 days).

Subacute (24 hours)

.

Most studies included in this review reported findings at 24 hours post-ketamine administration (k = 10). Of these studies, four reported a significant effect of ketamine in reducing anxiety symptoms compared to placebo: three using the HAM-A scale in mood disorder patients and one using the Impact of Event Scale–Revised (IES-R; Weiss & Marmar, 1997) in PTSD patients (Feder et al., 2014; Lapidus et al., 2014; Nugent et al., 2019; Zarate et al., 2012). All four studies used a crossover design.

Respectively, Lapidus et al. (2014) (n = 20) and Nugent et al. (2019) (n = 60) found intranasal and intravenous ketamine treatments to be more effective in reducing HAM-A scores in

MDD patients than placebo at 24 hours post-administration. Similarly, Zarate et al. (2012) (n = 15) found intravenous ketamine to be superior to placebo at symptom reduction using this scale at 24 hours in bipolar disorder patients. Lastly, Feder et al. (2014) (n = 41) reported significant drug group differences at 24 hours on the IES-R when comparing the efficacy of 0.5 mg/kg ketamine with an active placebo, midazolam (0.045 mg/kg) in 41 patients with chronic PTSD.

Results of the meta-analysis of 10 studies with available group-level data (**Figure 3B**) showed that there was a significant difference in anxiety scores between the ketamine (n = 179) and placebo (n = 178) groups (SMD: -0.43, 95% CI: [-0.65, - 0.22], p < 0.001). No significant heterogeneity was reported ($I^2 = 0\%$, p = 0.76).

Sustained (7-14 days)

There were mixed findings from the nine studies which looked at time points between seven- and 14- days post-infusion – four reported significant findings (Feder et al., 2021; Rodriguez et al., 2013; Zarate et al., 2012; Taylor et al., 2018), and three reported no significance (Abdallah et al., 2022; Feder et al., 2014; Nugent et al., 2018).

Feder et al. (2021) (n = 30) used scores from the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2018) to assess symptom severity one week into treatment with multiple doses of intravenous ketamine (measured after fourth infusion) and at the end of treatment. Analysis revealed significantly lower total scores in the ketamine group compared to the midazolam group at one week post-first infusion, which was sustained at two-weeks post-first infusion. Two studies with significant findings recruited participants with an anxiety disorder diagnosis. Rodriguez et al. (2013) (n = 15) found that those who received ketamine reported significantly lower means on the OCD-VAS at seven days postinfusion. Meanwhile, Taylor and colleagues (2018) (n = 18) found that, starting at 10 days post-infusion, participants with SAD receiving ketamine demonstrated significantly greater reductions in overall Liebowitz Social Anxiety Scale (LSAS; Heimberg et al., 1999) scores compared to those receiving placebo.

Both Murrough et al. (2015) and Zarate et al. (2012) explored ketamine's efficacy in patients diagnosed with mood disorders. In patients with mood disorders and clinically significant suicidal ideation, Murrough and colleagues (2015) (n = 24) found that mean Concise Associated Symptoms Tracking scale (CAST; Trivedi et al., 2011) subscale scores pertaining to anxiety (irritability, anxiety and panic) were numerically lower in the ketamine compared to midazolam group on each subscale at seven days, but the researchers did not analyse the CAST subscale scores statistically. Meanwhile, Zarate et al. (2012) reported significantly lower scores in subjects who had received ketamine as opposed to placebo on the VAS-Anxiety scale at days seven and 14 post-ketamine administration.

The meta-analysis included nine studies for which data were available (**Figure 3C**) and included 157 patients who had received ketamine and 150 patients who had received placebo. Analysis revealed that mean anxiety scores were significantly lower in the ketamine group compared to those in the placebo group (SMD: -0.43 [95% CI: -0.65, -0.20], p < 0.01). There was no significant heterogeneity among studies (I² = 0%, p < 0.001).

Effects beyond 14 days

Of the four studies which explored the efficacy of ketamine beyond two weeks, two studies reported significant treatment group differences (Norbury et al., 2021; Pradhan et al., 2018), whilst two reported non-significance (Pradhan et al., 2017; Fallon et al., 2018).

A repeated dose study carried out by Norbury and colleagues (2021) found CAPS-5 scores to be significantly lower at 16 days post-first dose in PTSD patients who had received ketamine than those who had received midazolam. Results revealed a significant session-by-drug interaction on CAPS-5 scores ($F_{1,57} = 6.58$, p = 0.013). Also exploring a prolonged treatment response were the Pradhan studies (Pradhan et al., 2017 & 2018), who measured Clinical Administered PTSD Scale (CAPS; Blake et al., 1995) and PTSD Checklist for DSM-IV (PCL; Weathers et al., 1993) scores weekly until relapse. In the 2017 study, patients receiving ketamine had a more sustained response (33 ± 22.98 days) than those who received placebo (25 ± 16.8 days), though this difference was non-significant (p = 0.545). In their 2018, the difference in length of response demonstrated a similar pattern (34.44 ± 19.12

days in the ketamine group and 16.50 ± 11.39 in the placebo group), however the difference was significant (p = 0.022).

Correlation between improvement in anxiety and depression scores

Seven studies provided depression and anxiety data at the subacute time point and six studies provided this data at sustained time point, leading to 182 and 175 participants included in each analysis respectively. A linear regression analysis was conducted and found that there was a significant correlation between percentage improvement in anxiety and depression scores at the subacute time point ($R^2 = 0.621$, p = 0.035, Figure 4A) and at the sustained time point (R² = 0.773, *p* = 0.021; **Figure 4B**).

Correlation between improvement in anxiety and peak dissociation

We sought to explore the relationship between peak dissociation and anxiety scores by correlating peak Clinician-Administered Dissociative States Scale (CADSS; Bremner et al., 1998) scores with percentage improvement in anxiety at the subacute and sustained time points. All peak CADSS scores were during infusion, except for Taylor et al. (2018), which was measured at one-hour post-ketamine administration.

At 24 hours post-administration, data from 222 participants was pooled to be included in the analysis. Results revealed no significant correlation between peak level of dissociation and improvement in anxiety symptoms ($R^2 = 0.011$, p = 0.808; Figure 4C). Similarly, at 7-14 days post-administration, where data from 237 participants were pooled, there was no significant correlation between the two scores ($R^2 = 0.171$, p = 0.268; Figure 4D).




Figure 4. Exploratory analysis of the correlation between ketamine's (A) anxiolytic and antidepressant effects at 24 hours (significant positive correlation; $R^2 = 0.621$, p = 0.035); (B) anxiolytic and antidepressant effects at 7-14 days (significant positive correlation; $R^2 =$ 0.773, p = 0.021; (C) anxiolytic effects at 24 hours and peak Clinician-Administered Dissociative States Scale (CADSS) scores (no correlation; $R^2 = 0.011$, p = 0.808); (D) anxiolytic effects at 7-14 days and peak CADSS scores (no correlation; $R^2 = 0.171$, p =0.268).

Lead author	Sample size (n)	Blinding	Sample disorder	Medication	Study design	Ketamine (type, dose and route)	Single or repeated dose	Placebo (dose and route)	Primary/ Secondary measure(s)	Anxiety scale in meta- analysis	Time stamp included in meta- analysis																									
Abdallah et al. (2022)	158		Post-Traumatic Stress Disorder	Concomitant medication	Parallel group	Racemic Intravenous (0.5 mg/kg; 0.2 mg/kg)	Repeated	Saline solution Intravenous	PCL-5: Primary; CAPS-5: Secondary	PCL-5	Subacute (24 hrs) Sustained (day 7)																									
Dadabayev et al. (2020)	21		Post-Traumatic Stress Disorder and chronic pain	Concomitant medication	Parallel group	Racemic Intravenous (0.5 mg/kg)	Single	Ketorolac 15mg Intravenous	IES-R: Primary	IES-R	Subacute (24 hrs) Sustained (day 7)																									
Fallon et al. (2018)	214	blinded	Cancer-related neuropathic pain	Concomitant medication	Parallel group	Racemic Oral (Various doses)	Single	Inert placebo (Various doses) Oral	HADS: Secondary	x	x																									
Feder et al. (2014)	41	Double-blinded	Double-	Double-	Double-	Double-	Double	Double	Double	Double	Double-	Double-	Double-	Double-	Double	Double-	Double	Post-Traumatic Stress Disorder	Concomitant medication	Crossover	Racemic Intravenous (0.5 mg/kg)	Single	Midazolam (0.045 mg/kg) Intravenous	IES-R: Primary	IES-R*	Subacute (24 hrs) Sustained (day 7)										
Feder et al. (2021)	30		Post-Traumatic Stress Disorder	Concomitant medication	Parallel group	Racemic Intravenous (0.5 mg/kg)	Repeated	Midazolam (0.045 mg/kg) Intravenous	CAPS-5: Primary IES-R: Secondary	Subacute: IES-R; Sustained: CAPS-5	Subacute (24 hrs) Sustained (14 days)																									
Lapidus et al. (2014)	20		Treatment- Resistant Depression	Concomitant medication	Crossover	Racemic Intranasal (50 mg)	Single	Saline solution Intravenous	HAM-A: Secondary	X	X																									

Murrough et al. (2015)	24	Mood disorders with suicidal ideation	Concomitant medication	Parallel group	Racemic Intravenous (0.5 mg/kg)	Single	Midazolam (0.045 mg/kg) Intravenous	CAST: Secondary	CAST - Anxiety subscale	Subacute (24 hrs) Sustained (day 7)
Norbury et al. (2021)	21	Post-Traumatic Stress Disorder	Concomitant medication	Parallel group	Racemic Intravenous (0.5 mg/kg)	Multiple dose	Midazolam (0.045 mg/kg) Intravenous	CAPS-5: Primary	x	x
Nugent et al. (2019)	60	Treatment- Resistant Depression	Unmedicated	Crossover	Racemic Intravenous (0.5 mg/kg)	Single dose	Saline solution Intravenous	HAM-A: Secondary	HAM-A	Acute (230 mins) Subacute (24 hrs) Sustained (day 7)
Pradhan et al. (2017)	10	Post-Traumatic Stress Disorder and Treatment- Resistant Depression comorbidity	Concomitant medication	Crossover	Racemic Intravenous (0.5 mg/kg)	Single dose	Saline solution Intravenous	PCL, CAPS: Primary	PCL	Acute (4 hrs) Subacute (24 hrs)
Pradhan et al. (2018)	10	Post-Traumatic Stress Disorder	Concomitant medication	Parallel group	Racemic Intravenous (0.5 mg/kg)	Single dose	Saline solution Intravenous	PCL, CAPS: Primary	PCL	Subacute (24 hrs)
Rodriguez et al. (2013)	15	Obsessive- Compulsive Disorder	Unmedicated	Crossover	Intravenous (0.5 mg/kg)	Single dose	Saline solution Intravenous	OCD-VAS, Y- BOCS: Primary	Acute: OCD-VAS* Sustained: Y-BOCS	Acute (230 mins) Sustained (day 7)




Table 1.Study characteristics. Abbreviations: PCL, Posttraumatic Stress Disorder Checklist; PCL-5, Posttraumatic Stress Disorder Checklist for DSM-5; CAPS, Clinical Administered PTSD Scale;CAPS-5, Clinically Administered Posttraumatic Stress Disorder Scale for DSM-5; IES-R, Impact of Events Scale-Revised; HAM-A, Hamilton Anxiety Rating Scale; CAST, Concise AssociatedSymptoms Tracking scale ; Y-BOCS, Yale-Brown Obsessive Compulsive Scale; OCD-VAS, Obsessive Compulsive Disorder-Visual Analogue Scale ; Anxiety-VAS; Anxiety-Visual Analogue Scale;LSAS, Liebowitz Social Anxiety Scale; STAI-S, State-Trait Anxiety Subscale. * indicates that the value included in meta-analysis was estimated.

Discussion

This is the first transdiagnostic systematic review and meta-analysis of RCTs to assess the temporal profile of ketamine's anxiolytic effects after a single dose. Of the 14 studies included in the systematic review and meta-analysis, seven studies assessed ketamine's anxiolytic effects in PTSD; five in mood disorders; two in anxiety disorders; and two in either chronic or cancer-related pain. Results suggest that ketamine is an efficacious treatment for anxiety symptoms across this range of settings. Ketamine's anxiolytic effect typically emerged after three to four hours and continued to be significantly superior relative to placebo at 24 hours and 7-14 days post-administration. Our findings suggest that single ketamine infusions could therefore offer both rapid and sustained improvement in anxiety. This work builds on previous systematic reviews and meta-analyses supporting ketamine's use in anxiety disorders (Banov et al., 2020; Tully et al., 2022; Whittaker et al., 2021).

Seven studies reported data <12 hours after administration. Our results at this acute time point support the conclusions made by both preclinical and clinical studies that ketamine may result in rapid reductions in anxiety (Riehl et al., 2011; Glue et al., 2017). The earliest significant effect was reported by Zarate and colleagues (2012) at 40 minutes post-infusion with the majority of studies measuring anxiety symptoms at this time point reporting a significant effect at three to four hours. This corroborates the finding by Glue and colleagues (2017) in an open-label study, where ketamine administration led to marked improvements in anxiety scores at one-hour post-dose in patients with generalised anxiety disorder and/or social anxiety disorder.

10 studies reported data at 24 hours post-administration – the modal time point in the meta-analysis – where ketamine again had a beneficial effect compared to placebo. This aligns with results from responder data, which provides an additional insight into whether a drug provides clinically meaningful symptom relief. Glue and colleagues showed that patients with SAD and GAD show a higher likelihood of response at 24 hours after ketamine compared to midazolam (Glue et al., 2020).

Nine studies reported data at 7-14 days after administration. The sustained time point had the most RCTs report significant drug differences out of all time points. This suggests that ketamine has anxiolytic effects which last through one to two weeks post-treatment. As such, our findings closely match the literature exploring the drug's efficacy in depression, which has found ketamine to have an anti-depressant effect lasting 7-14 days after a single dose (Coyle & Laws, 2015)

We endeavoured to examine any anxiolytic effects beyond 14 days. However, very few studies met our inclusion criteria (n = 4). From the included studies, there is evidence that ketamine continues to be superior to placebo beyond two weeks post-administration, with one study finding evidence of an anxiolytic effect up to one-month after a single dose (Pradhan et al., 2018). Coupling these results with the optimism in findings from earlier time points, future studies should further explore ketamine's sustained anxiolytic efficacy beyond that of two weeks.

To date, most research into the psychiatric utility of ketamine has focused on depression. We conducted an exploratory analysis into the relationship between depression and anxiety improvements at both the subacute and sustained time point. If the anxiolytic and antidepressant effects of ketamine share similar mechanisms, one might expect to see a strong correlation between the improvements in both symptoms. Results revealed a significant correlation between mean percentage improvements in depression and anxiety at both the subacute (k = 7) and sustained time points (k = 6). Future imaging work could explore whether the same or distinct neural circuits which are related to ketamine's effects on distinct symptom clusters.

We also analysed whether there was any link between ketamine's anxiolytic effect and its peak dissociative effects as measured using the CADSS, at both the subacute and sustained time points. Research on the relationship between dissociation and therapeutic outcomes of ketamine treatment is equivocal. There are documented concerns that ketamine's dissociative effects may negatively impact anxiety outcomes (Carlson et al., 2012; Coutinho et al., 2016; Schönberg et al., 2005 & 2008). Conversely, there is the suggestion that the degree of dissociation is important in ketamine's therapeutic effects, and specifically that

greater levels of dissociation may lead to more improvement in depression symptoms (Correia-Melo et al., 2017; Luckenbaugh et al., 2014; Sos et al., 2013). Our analysis showed no significant relationship between the two at either time point, suggesting that ketamine's anxiolytic effects are independent from its dissociative effects. Indeed, there is research which has also concluded no relationship between peak dissociation and therapeutic effect (Berman et al., 2000; Ballard & Zarate, 2020; Fava et al., 2020; Lapidus et al., 2014; Włodarczyk et al., 2021). Nevertheless, our analysis was done using a small number of data points and more work should be done to further investigate these conclusions.

Several limitations of our study are of note. First is the high risk of bias in most of the included studies. Nine out of the 11 studies were reported as having high risk of bias, mainly because of unblinding of patients and outcome assessors, or selective reporting of data from secondary measures. The prevalence of unblinding in the included studies speaks to the difficulty in achieving effective blinding in studies exploring ketamine's efficacy. Only five studies included an active placebo, and future research would benefit from the use of active placebos as controls. A second limitation is the presence of moderate heterogeneity in the meta-analysis of data at the acute time point ($I^2 = 50\%$) which implies clinical and/or methodological diversity in the included studies and implicates our conclusions. This may be due to low sample sizes (Inthount et al., 2015), and differences in study protocols (including the precise time point assessed within these windows) and disorders (though the latter is inherent in prioritising a transdiagnostic approach). While heterogeneity was low in the other two time points ($I^2 = 0\%$ in subacute and sustained analyses), the potential for issues in comparability should not be ignored. Future work should aim for larger sample sizes and to carry out sensitivity analyses exploring the influence of diversity. Third, our metaanalyses consisted of findings from parallel arm and crossover studies. When carryover effects were found in crossover trials, data were limited to exclusively the first phase of the study; if not, collapsed data from both phases were used. It is possible that this variability introduced bias into our analysis. Finally, although this review intended to include studies assessing ketamine's anxiolytic efficacy in settings such as chronic pain and palliative care, only one study in this context was eligible for inclusion (Dadabayev et al., 2020).

Conclusion

Our meta-analysis demonstrates ketamine's anxiolytic effects emerged rapidly at three to four hours post-administration and persisted for up to two weeks. This study is the first review to consider the efficacy of ketamine in anxiety symptoms across multiple time points using a transdiagnostic approach. By limiting our review to randomised control trials, which is considered as the highest quality of evidence (McErlean et al., 2022), we were able to eliminate any inconsistency due to methodological variation and identify areas of true uncertainty in the literature. Future RCTs should acknowledge that, in clinical settings, ketamine is most often administered in multiple doses and should explore anxiolytic effects after repeated dosing, as well as replicate our work to continue to elucidate the medication's time course of action. This could help to identify the best administration pattern.

Author contributions

Conceptualisation, A.H.Y., L.A.; Methodology, H.H., K.M., L.A.J., R.S., A.H.Y., L.A.; Formal analysis, H.H., K.M., R.S., L.A.; Investigation, H.H., K.M., L.A.; Writing – original draft, H.H., K.M., L.A.; Writing – review and editing, H.H., K.M., L.A.J., R.S., A.H.Y., L.A.; Visualisation, H.H., K.M., L.A.; Funding acquisition, A.H.Y.; Resources, A.H.Y.; Supervision, A.H.Y., L.A.

Funding statement

This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Dr Luke A Jelen is a Medical Research Council (MRC) Clinical Research Training Fellow (MR/T028084/1). Dr Laith Alexander is an NIHR Academic Clinical Fellow in Translational Psychiatry (ACF-2022-17-016).

Declaration of interests

HH, KM, LJ and LA have no conflicts of interest. In the last 3 years: RS declares an honorarium from Lundbeck. AHY declares honoraria for speaking from Astra Zeneca, Lundbeck, Eli Lilly, Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen; and research grant support from Janssen.

References

- Abdallah, C. G., Roache, J. D., Gueorguieva, R., Averill, L. A., Young-McCaughan, S., Shiroma, P. R., Purohit, P., Brundige, A., Murff, W., Ahn, K. H., Sherif, M. A., Baltutis, E. J., Ranganathan, M., D'Souza, D., Martini, B., Southwick, S. M., Petrakis, I. L., Burson, R. R., Guthmiller, K. B., López-Roca, A. L., ... Krystal, J. H. (2022). Dose- related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo controlled multi-center clinical trial. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 47*(8), 1574–1581. https://doi.org/10.1038/s41386-022-01266-9
- Aitken R. C. (1969). Measurement of feelings using visual analogue scales.
 Proceedings of the Royal Society of Medicine, 62(10), 989–993.
- 3. American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). <u>https://doi</u>-

org.ezproxy.frederick.edu/10.1176/appi.books.9780890425596

- Ballard, E. D., & Zarate, C. A., Jr (2020). The role of dissociation in ketamine's antidepressant effects. *Nature communications*, *11*(1), 6431. <u>https://doi.org/10.1038/s41467-020</u>-20190- 4
- Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., Sanacora, G., Miguel, E. C., Sampaio, A. S., & Quarantini, L. C. (2022). Ketamine in the Treatment of Obsessive Compulsive Disorder: A Systematic Review. *Harvard review of psychiatry*, *30*(2), 135–145. https://doi.org/10.1097/HRP.00000000000330
- Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. *Dialogues in clinical neuroscience*, *17*(3), 327–335. <u>https://doi.org/10.31887/DCNS.2015.17.3/bbandelow</u>
- Banov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2020). Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a

> review of the literature. *CNS spectrums*, *25*(3), 331–342. https://doi.org/10.1017/S1092852919001238

- Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. *Biological psychiatry*, *47*(4), 351–354. <u>https://doi.org/10.1016/s0006-3223(99)00230-9</u>
- Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., &Keane, T. M. (1995). The development of a Clinician-Administered PTSD Scale. *Journal of traumatic stress*, 8(1), 75–90. <u>https://doi.org/10.1007/BF02105408</u>
- Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998). Measurement of dissociative states with the Clinician Administered Dissociative States Scale (CADSS). *Journal of traumatic stress*, *11*(1), 125–136. <u>https://doi.org/10.1023/A:1024465317902</u>
- Bystritsky A. (2006). Treatment-resistant anxiety disorders. *Molecular psychiatry*, *11*(9), 805 814. https://doi.org/10.1038/sj.mp.4001852
- Carlson, E. B., Dalenberg, C., & McDade-Montez, E. (2012). Dissociation in posttraumatic stress disorder part 1: Definitions and review of research. *Psychological Trauma: Theory, Research, Practice, and Policy, 4*(5), 479–489. <u>https://doi.org/10.1037/a0027748</u>
- Cassano, G. B., Baldini Rossi, N., & Pini, S. (2002). Psychopharmacology of anxiety disorders. *Dialogues in clinical neuroscience*, 4(3), 271–285. <u>https://doi.org/10.31887/DCNS.2002.4.3/gcassano</u>
- 14. Correia-Melo, F. S., Argolo, F. C., Araújo-de-Freitas, L., Leal, G. C., Kapczinski, F., Lacerda, A. L., & Quarantini, L. C. (2017). Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. *Neuropsychiatric disease and treatment*, *13*, 1627–1632. <u>https://doi.org/10.2147/NDT.S135623</u>
- 15. Coutinho, J. F., Fernandesl, S. V., Soares, J. M., Maia, L., Gonçalves, Ó. F., & Sampaio,
 A. (2016). Default mode network dissociation in depressive and anxiety
 states. *Brain imaging and behavior*, *10*(1), 147–157.
 https://doi.org/10.1007/s11682-015-9375-7

- 16. Coyle, C.M. and Laws, K.R. (2015) "The use of ketamine as an antidepressant: A systematic review and meta-analysis," *Human Psychopharmacology: Clinical and Experimental*, 30(3), pp. 152–163. Available at: https://doi.org/10.1002/hup.2475.
- Dadabayev, A. R., Joshi, S. A., Reda, M. H., Lake, T., Hausman, M. S., Domino, E., & Liberzon, I. (2020). Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial. *Chronic stress (Thousand Oaks, Calif.), 4,* 2470547020981670. <u>https://doi.org/10.1177/2470547020981670</u>
- Drysdale, A. T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., Fetcho, R. N., Zebley, B., Oathes, D. J., Etkin, A., Schatzberg, A. F., Sudheimer, K., Keller, J., Mayberg, H. S., Gunning, F. M., Alexopoulos, G. S., Fox, M. D., Pascual-Leone, A., Voss, H. U., ... Liston, C. (2017). Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature Medicine, 23(1), 28. https://doi.org/10.1038/nm.4246
- Fallon, M. T., Wilcock, A., Kelly, C. A., Paul, J., Lewsley, L. A., Norrie, J., & Laird, B. (2018). Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial. *JAMA oncology*, 4(6), 870–872. <u>https://doi.org/10.1001/jamaoncol.2018.0131</u>
- 20. Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., Murrough, J., Debattista, C., Schatzberg, A. F., Trivedi, M. H., Jha, M. K., Sanacora, G., Wilkinson, S. T., & Papakostas, G. I. (2020). Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). *Molecular psychiatry*, *25*(7), 1592—1603.https://doi.org/10.1038/s41380-018-0256-5
- Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Brallier, J., Pietrzak, R. H., Murrough, J. W., & Charney, D. S. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. *The American journal of psychiatry*, *178*(2), 193–202. <u>https://doi.org/10.1176/appi.ajp.2020.20050596</u>

 Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., Aan Het Rot, M., Lapidus, K. A., Wan, L. B., Iosifescu, D., & Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. *JAMA psychiatry*, 71(6), 681–688. <u>https://doi.org/10.1001/jamapsychiatry.2014.62</u>

23. Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 31(10).

https://doi.org/10.1177/0269881117705089

24. Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6).

https://doi.org/10.1177/0269881118762073

- 25. Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2020). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive controlled replication study. *Journal of psychopharmacology (Oxford, England), 34*(3), 267–272. https://doi.org/10.1177/0269881119874457
- 26. Hamilton, M. (1959). The assessment of anxiety states by rating. *The British journal of medical psychology*, *32*(1), 50–55. <u>https://doi.org/10.1111/j.2044</u>-8341.1959.tb00467.x
- 27. Heimberg, R. G., Horner, K. J., Juster, H. R., Safren, S. A., Brown, E. J., Schneier, F. R., & Liebowitz, M. R. (1999). Psychometric properties of the Liebowitz Social Anxiety Scale. *Psychological medicine*, *29*(1), 199–212. <u>https://doi.org/10.1017/s0033291798007879</u>
- 28. Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A., Cochrane Bias Methods Group, & Cochrane Statistical Methods Group (2011). The Cochrane

Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* (*Clinical research ed.*), 343, d5928. <u>https://doi.org/10.1136/bmj.d5928</u>

29. Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010). Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders. American Journal of Psychiatry, 167(7), 748–751.

https://doi.org/10.1176/appi.ajp.2010.09091379

- 30. Inthout, J., Ioannidis, J. P. A., Borm, G. F., & Goeman, J. J. (2015). Small studies are more heterogeneous than large ones: A meta-meta-analysis. Journal of Clinical Epidemiology, 68(8). <u>https://doi.org/10.1016/j.jclinepi.2015.03.017</u>
- 31. Kelly, B., McClement, S., & Chochinov, H. M. (2006). Measurement of psychological distress in palliative care. *Palliative medicine*, *20*(8), 779–789. <u>https://doi.org/10.1177/0269216306072347</u>
- 32. Kotov, R., Krueger, R. F., Watson, D., Achenbach, T. M., Althoff, R. R., Bagby, R. M., Brown, T. A., Carpenter, W. T., Caspi, A., Clark, L. A., Eaton, N. R., Forbes, M. K., Forbush, K. T., Goldberg, D., Hasin, D., Hyman, S. E., Ivanova, M. Y., Lynam, D. R., Markon, K., ... Zimmerman, M. (2017). The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. Journal of Abnormal Psychology, 126, 454–477.

https://doi.org/10.1037/abn0000258

 Kozlov, E., Phongtankuel, V., Prigerson, H., Adelman, R., Shalev, A., Czaja, S., Dignam, R., Baughn, R., & Reid, M. C. (2019). Prevalence, Severity, and Correlates of Symptoms of Anxiety and Depression at the Very End of Life. Journal of Pain and Symptom Management, 58(1).

https://doi.org/10.1016/j.jpainsymman.2019.04.012

34. Lapidus, K. A., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014). A randomized controlled trial of intranasal ketamine in major depressive disorder. *Biological psychiatry*, 76(12), 970–976. <u>https://doi.org/10.1016/j.biopsych.2014.03.026</u>

- 35. Liriano, F., Hatten, C., & Schwartz, T. L. (2019). Ketamine as treatment for post traumatic stress disorder: a review. *Drugs in context*, *8*, 212305. <u>https://doi.org/10.7573/dic.212305</u>
- 36. Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects?. *Journal of affective disorders*, 159, 56–61.<u>https://doi.org/10.1016/j.jad.2014.02.017</u>
- 37. Marcantoni, W. S., Akoumba, B. S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., & Beauchamp, S. (2020). A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 2019. *Journal of affective disorders*, 277, 831–841. <u>https://doi.org/10.1016/j.jad.2020.09.007</u>
- 38. McErlean, M., Samways, J., Godolphin, P. J., & Chen, Y. (2022). The reporting standards of randomised controlled trials in leading medical journals between 2019 and 2020: a systematic review. In Irish Journal of Medical Science. <u>https://doi.org/10.1007/s11845022-02955-6</u>
- 39. McWilliams, L. A., Cox, B. J., & Enns, M. W. (2003). Mood and anxiety disorders associated with chronic pain: An examination in a nationally representative sample. Pain, 106(1–2), 127 133. <u>https://doi.org/10.1016/s0304-3959(03)00301-4</u>
- 40. Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., Price, R. B., Perez, A. M., Brallier, J. W., Rodriguez, G. J., Goodman, W. K., Iosifescu, D. V., & Charney, D. S. (2015). Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. *Psychological medicine*, *45*(16), 3571–3580. https://doi.org/10.1017/S0033291715001506
- 41. Neel, C., Lo, C., Rydall, A., Hales, S., & Rodin, G. (2015). Determinants of death anxiety in patients with advanced cancer. BMJ Supportive and Palliative Care, 5(4). <u>https://doi.org/10.1136/bmjspcare-2012-000420</u>
- 42. Norbury, A., Rutter, S. B., Collins, A. B., Costi, S., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Glasgow, A. M., Brallier, J., Shin, L. M., Charney, D. S., Murrough, J. W., & Feder, A. (2021). Neuroimaging correlates and

> predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 46*(13), 2266–2277. <u>https://doi.org/10.1038/s41386-021-01104-4</u>

- Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A., Jr (2019). Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. *Molecular psychiatry*, 24(7), 1040–1052. <u>https://doi.org/10.1038/s41380-018-0028-2</u>
- 44. Nutt D. J. (2005). Overview of diagnosis and drug treatments of anxiety disorders.*CNS spectrums*, *10*(1), 49–56. https://doi.org/10.1017/s1092852900009901
- 45. Park, S.-C., & Kim, D. (2020). The Centrality of Depression and Anxiety Symptoms in Major Depressive Disorder Determined Using a Network Analysis. Journal of Affective Disorders, 271, 19–26. <u>https://doi.org/10.1016/j.jad.2020.03.078</u>
- 46. Pradhan, B., Mitrev, L., Moaddell, R., & Wainer, I. W. (2018). d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. *Biochimica et biophysica acta. Proteins and proteomics*, 1866(7), 831–839. https://doi.org/10.1016/j.bbapap.2018.03.006
- 47. Pradhan, B., Wainer, I., Moaddel, R., Torjman, M., Goldberg, M., Sabia, M., Parikh, T., & Pumariega, A. (2017). Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial. *Asia Pacific Journal of Clinical Trials: Nervous System Diseases*, 2(3), 80.

https://link.gale.com/apps/doc/A580721878/HRCA?u=anon~29af0865&sid googleScholar&xid=f3391511

- 48. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.
- 49. Riehl, R., Kyzar, E., Allain, A., Green, J., Hook, M., Monnig, L., Rhymes, K., Roth, A.,
 Pham, M., Razavi, R., DiLeo, J., Gaikwad, S., Hart, P., & Kalueff, A. v. (2011).
 Behavioral and physiological effects of acute ketamine exposure in adult

zebrafish. Neurotoxicology and Teratology, 33(6).

https://doi.org/10.1016/j.ntt.2011.05.011

50. Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011). Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive- compulsive disorder. *The Journal of clinical psychiatry*, 72(4), 567–569. https://doi.org/10.4088/JCP.10I06653

51. Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive compulsive disorder: proof-of-concept. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38*(12), 2475–2483. https://doi.org/10.1038/npp.2013.150

- 52. Roth, A. J., & Massie, M. J. (2007). Anxiety and its management in advanced cancer. *Current opinion in supportive and palliative care*, 1(1), 50–56. https://doi.org/10.1097/SPC.0b013e32813aeb23
- Schönenberg, M., Reichwald, U., Domes, G., Badke, A., & Hautzinger, M. (2005). Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. *Psychopharmacology*, *182*(3), 420–425. <u>https://doi.org/10.1007/s00213</u>-005-0094-4
- 54. Schönenberg, M., Reichwald, U., Domes, G., Badke, A., & Hautzinger, M. (2008).
 Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims. *Journal of psychopharmacology (Oxford, England)*, 22(5), 493–497. https://doi.org/10.1177/0269881107082481
- 55. Scipilot Pty. Ltd. Released 2021. Syras systematic review screening software. Sydney, Australia. Available at <u>https://syras.org/</u>
- 56. Sos, P., Klirova, M., Novak, T., Kohutova, B., Horacek, J., & Palenicek, T. (2013). Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. *Neuroendocrinology letters*, 34(4), 287–293.
- 57. Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., & Bloch, M. H. (2018). Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, *43*(2), 325–333. https://doi.org/10.1038/npp.2017.194

- 58. Trivedi, M. H., Wisniewski, S. R., Morris, D. W., Fava, M., Kurian, B. T., Gollan, J. K., Nierenberg, A.A., Warden, D., Gaynes, B. N., Luther, J. F., & Rush, A. J. (2011). Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. The Journal of clinical psychiatry, 72(6), 765–774. https://doi.org/10.4088/JCP.11m06840
- 59. Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. (2022). Ketamine treatment for refractory anxiety: A systematic review. British journal of *clinical pharmacology*, 10.1111/bcp.15374. Advance online publication. https://doi.org/10.1111/bcp.15374
- 60. Weathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychological assessment, 30(3), 383–395. https://doi.org/10.1037/pas0000486
- 61. Weathers, F. W., Litz, B. T., Keane, T. M., Palmieri, P. A., Marx, B. P., & Schnurr, P. P. (2013). The PTSD Checklist for DSM-5 (PCL-5) – Standard [Measurement instrument]. Available from https://www.ptsd.va.gov/
- 62. Weathers, Frank & Litz, Brett & Herman, Debra & Huska, J.A. & Keane, Terence. (1993). The PTSD Checklist (PCL): Reliability, validity, and diagnostic utility. Paper Presented at the Annual Convention of the International Society for Traumatic Stress Studies.
- 63. Weiss, D. S., & Marmar, C. R. (1997). The Impact of Event Scale-Revised. In J. P. Wilson & T. M. Keane (Eds.), Assessing psychological trauma and PTSD (pp. 399–411). The Guilford Press.
- 64. Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021). Systematic review and meta- analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic advances in psychopharmacology, 11, 20451253211056743. https://doi.org/10.1177/20451253211056743

 Włodarczyk, A., Cubała, W. J., Gałuszko-Węgielnik, M., & Szarmach, J. (2021). Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. *Medicine*, *100*(29), e26769. https://doi.org/10.1097/MD.00000000026769

- 66. Zarate, C. A., Jr, Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biological psychiatry*, *71*(11), 939–946. <u>https://doi.org/10.1016/j.biopsych.2011.12.010</u>
- 67. Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. *Acta* psychiatrica Scandinavica, 67(6), 361–370. <u>https://doi.org/10.1111/j.1600</u>-0447.1983.tb09716.x




FIGURE 2.

	Randomization process	Period and carryover effects	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall	
Abdallah 2022								
Dadabaxey 2020								
Fallon 2018								
Feder 2014								
Feder 2021								
Lapidus 2014								
Murrough 2015								
Norbury 2021								
Nugent 2019								
Pradhan 2017								
Pradhan 2018								
Rodriguez 2013								
Taylor 2018								
Zarate 2012								

Low risk	
Some Concerns	
High risk	
Not applicable	

FIGURE 3.

А.	Ketamine		Р	Placebo			Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Rodriguez 2013	2.2	1.697	8	6.1	0.926	7	11.9%	-2.63 [-4.12, -1.14]		
Zarate 2012	11.93	5.89	14	19.17	4.76	12	22.8%	-1.30 [-2.16, -0.44]	_	
Taylor 2018	64.8	20.1	9	85.1	22.2	9	20.0%	-0.91 [-1.90, 0.07]		
Pradhan 2017	37.8	20.34	5	55.2	13.31	4	12.8%	-0.88 [-2.30, 0.55]		
Nugent 2019	14.36	6.67	33	17.35	4.44	31	32.5%	-0.52 [-1.02, -0.02]		
Total (95% CI)			69			63	100.0%	-1.07 [-1.68, -0.46]	•	
Heterogeneity: Tau ² =	= 0.23; C	$chi^2 = 8$.21, df	= 4 (P =	= 0.08);	$l^2 = 51$.%			
Test for overall effect	: Z = 3.4	4 (P = 0)	0.0006)						
									Favours ketamine Favours placebo	

В.

	Ketamine				Placebo			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Zarate 2012	13.36	6.91	14	20	4.55	12	6.4%	-1.08 [-1.92, -0.25]	
Taylor 2018	66.11	19.572	9	86.25	21.75	9	4.6%	-0.93 [-1.91, 0.06]	
Murrough 2015	6.1	2.9	12	8.4	3.2	12	6.5%	-0.73 [-1.56, 0.10]	
Nugent 2019	15.45	7.06	33	18.37	4.78	30	17.8%	-0.47 [-0.98, 0.03]	
Feder 2014	14.7	23.452	19	24	17.436	22	11.6%	-0.45 [-1.07, 0.18]	
Feder 2021	19.7	15.2	15	24.8	13.1	15	8.6%	-0.35 [-1.07, 0.37]	
Abdallah 2022	31.01	20.7	51	37.93	20.8	54	30.1%	-0.33 [-0.72, 0.05]	
Pradhan 2017	25.6	3.78	5	26.6	7.63	4	2.6%	-0.15 [-1.47, 1.16]	
Pradhan 2018	25.8	8.15	10	26.3	6.82	10	5.8%	-0.06 [-0.94, 0.81]	
Dabadayev 2020	36.3	17.28	11	37	15.78	10	6.1%	-0.04 [-0.90, 0.82]	
Total (95% CI)			179			178	100.0%	-0.43 [-0.65, -0.22]	•
Heterogeneity: Tau ² =	= 0.00; 0	Chi ² = 5.2	77, df =	9 (P =	0.76); I ²	= 0%			
Test for overall effect	z = 4.0	03 (P < 0	.0001)						Favours ketamine Favours placebo

C.

C.	Ke	etamine		Р	acebo			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Taylor 2018	67	20.7	9	87.75	23.16	9	5.4%	-0.90 [-1.88, 0.08]	
Feder 2021	22.5	14.4	15	33.2	11.8	15	9.3%	-0.79 [-1.54, -0.04]	
Rodriguez 2013	18.25	7.305	8	23.714	6.343	7	4.6%	-0.75 [-1.81, 0.31]	
Murrough 2015	6	2.6	12	8.2	3.9	12	7.7%	-0.64 [-1.47, 0.18]	
Feder 2014	25.76	19.4	19	36.32	13.73	15	10.8%	-0.60 [-1.29, 0.09]	
Zarate 2012	16.67	5.25	12	18.91	3.02	11	7.5%	-0.50 [-1.33, 0.34]	
Nugent 2019	17.55	6.68	20	20	4.85	17	12.2%	-0.41 [-1.06, 0.25]	
Dabadayev 2020	28.2	22.6	11	33.67	20.4	10	7.0%	-0.24 [-1.10, 0.62]	_
Abdallah 2022	35.18	21.02	51	38.26	20.95	54	35.5%	-0.15 [-0.53, 0.24]	
Total (95% CI)			157			150	100.0%	-0.43 [-0.65, -0.20]	•
Heterogeneity: Tau ² =	= 0.00; 0	Chi ² = 4	.93, df	= 8 (P =	0.77); I	$^{2} = 0\%$			
Test for overall effect	: Z = 3.6	66 (P =	0.0002)					Favours ketamine Favours placebo

FIGURE 4.

